These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 31904482)

  • 1. Inhibition of fatty acid catabolism augments the efficacy of oxaliplatin-based chemotherapy in gastrointestinal cancers.
    Wang Y; Lu JH; Wang F; Wang YN; He MM; Wu QN; Lu YX; Yu HE; Chen ZH; Zhao Q; Liu J; Chen YX; Wang DS; Sheng H; Liu ZX; Zeng ZL; Xu RH; Ju HQ
    Cancer Lett; 2020 Mar; 473():74-89. PubMed ID: 31904482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CPT2 downregulation triggers stemness and oxaliplatin resistance in colorectal cancer via activating the ROS/Wnt/β-catenin-induced glycolytic metabolism.
    Li H; Chen J; Liu J; Lai Y; Huang S; Zheng L; Fan N
    Exp Cell Res; 2021 Dec; 409(1):112892. PubMed ID: 34688609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carnitine palmitoyltransferase gene upregulation by linoleic acid induces CD4
    Brown ZJ; Fu Q; Ma C; Kruhlak M; Zhang H; Luo J; Heinrich B; Yu SJ; Zhang Q; Wilson A; Shi ZD; Swenson R; Greten TF
    Cell Death Dis; 2018 May; 9(6):620. PubMed ID: 29795111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AMPKα1 confers survival advantage of colorectal cancer cells under metabolic stress by promoting redox balance through the regulation of glutathione reductase phosphorylation.
    Wang YN; Lu YX; Liu J; Jin Y; Bi HC; Zhao Q; Liu ZX; Li YQ; Hu JJ; Sheng H; Jiang YM; Zhang C; Tian F; Chen Y; Pan ZZ; Chen G; Zeng ZL; Liu KY; Ogasawara M; Yun JP; Ju HQ; Feng JX; Xie D; Gao S; Jia WH; Kopetz S; Xu RH; Wang F
    Oncogene; 2020 Jan; 39(3):637-650. PubMed ID: 31530934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The synergistic effects of oxaliplatin and piperlongumine on colorectal cancer are mediated by oxidative stress.
    Chen W; Lian W; Yuan Y; Li M
    Cell Death Dis; 2019 Aug; 10(8):600. PubMed ID: 31395855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts.
    Nukatsuka M; Nakagawa F; Takechi T
    Anticancer Res; 2015 Sep; 35(9):4605-15. PubMed ID: 26254349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tubeimoside-I, an inhibitor of HSPD1, enhances cytotoxicity of oxaliplatin by activating ER stress and MAPK signaling pathways in colorectal cancer.
    Wu T; Yu Y; Tu X; Ye L; Wang J; Xie C; Kuang K; Yu Y; Zhuge W; Wang Z; Cui R; Zheng Y
    J Ethnopharmacol; 2025 Jan; 336():118754. PubMed ID: 39208999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ursolic acid enhances the therapeutic effects of oxaliplatin in colorectal cancer by inhibition of drug resistance.
    Zhang Y; Huang L; Shi H; Chen H; Tao J; Shen R; Wang T
    Cancer Sci; 2018 Jan; 109(1):94-102. PubMed ID: 29034540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elimination of chronic lymphocytic leukemia cells in stromal microenvironment by targeting CPT with an antiangina drug perhexiline.
    Liu PP; Liu J; Jiang WQ; Carew JS; Ogasawara MA; Pelicano H; Croce CM; Estrov Z; Xu RH; Keating MJ; Huang P
    Oncogene; 2016 Oct; 35(43):5663-5673. PubMed ID: 27065330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new herbal formula BP10A exerted an antitumor effect and enhanced anticancer effect of irinotecan and oxaliplatin in the colon cancer PDTX model.
    Kim J; Kim HY; Hong S; Shin S; Kim YA; Kim NS; Bang OS
    Biomed Pharmacother; 2019 Aug; 116():108987. PubMed ID: 31112870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genipin Enhances the Therapeutic Effects of Oxaliplatin by Upregulating BIM in Colorectal Cancer.
    Kim BR; Jeong YA; Jo MJ; Park SH; Na YJ; Kim JL; Jeong S; Yun HK; Kang S; Lee DH; Oh SC
    Mol Cancer Ther; 2019 Apr; 18(4):751-761. PubMed ID: 30787174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of capecitabine efficacy by oxaliplatin in human colorectal and gastric cancer xenografts.
    Sawada N; Kondoh K; Mori K
    Oncol Rep; 2007 Oct; 18(4):775-8. PubMed ID: 17786335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological Ascorbate Suppresses Growth of Gastric Cancer Cells with GLUT1 Overexpression and Enhances the Efficacy of Oxaliplatin Through Redox Modulation.
    Lu YX; Wu QN; Chen DL; Chen LZ; Wang ZX; Ren C; Mo HY; Chen Y; Sheng H; Wang YN; Wang Y; Lu JH; Wang DS; Zeng ZL; Wang F; Wang FH; Li YH; Ju HQ; Xu RH
    Theranostics; 2018; 8(5):1312-1326. PubMed ID: 29507622
    [No Abstract]   [Full Text] [Related]  

  • 14. Baicalin enhances the chemotherapy sensitivity of oxaliplatin-resistant gastric cancer cells by activating p53-mediated ferroptosis.
    Shao L; Zhu L; Su R; Yang C; Gao X; Xu Y; Wang H; Guo C; Li H
    Sci Rep; 2024 May; 14(1):10745. PubMed ID: 38730240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ethaselen synergizes with oxaliplatin in tumor growth inhibition by inducing ROS production and inhibiting TrxR1 activity in gastric cancer.
    Zhang H; Wu J; Yuan J; Li H; Zhang Y; Wu W; Chen W; Wang C; Meng S; Chen S; Huo M; He Y; Zhang C
    J Exp Clin Cancer Res; 2021 Aug; 40(1):260. PubMed ID: 34412665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ursolic acid synergistically enhances the therapeutic effects of oxaliplatin in colorectal cancer.
    Shan J; Xuan Y; Zhang Q; Zhu C; Liu Z; Zhang S
    Protein Cell; 2016 Aug; 7(8):571-85. PubMed ID: 27472952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (
    Combès E; Andrade AF; Tosi D; Michaud HA; Coquel F; Garambois V; Desigaud D; Jarlier M; Coquelle A; Pasero P; Bonnefoy N; Moreaux J; Martineau P; Del Rio M; Beijersbergen RL; Vezzio-Vie N; Gongora C
    Cancer Res; 2019 Jun; 79(11):2933-2946. PubMed ID: 30987998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TLR 7/8 agonist reverses oxaliplatin resistance in colorectal cancer via directing the myeloid-derived suppressor cells to tumoricidal M1-macrophages.
    Liu Z; Xie Y; Xiong Y; Liu S; Qiu C; Zhu Z; Mao H; Yu M; Wang X
    Cancer Lett; 2020 Jan; 469():173-185. PubMed ID: 31629935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. WBSCR22 confers oxaliplatin resistance in human colorectal cancer.
    Yan D; Tu L; Yuan H; Fang J; Cheng L; Zheng X; Wang X
    Sci Rep; 2017 Nov; 7(1):15443. PubMed ID: 29133897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NKX2-8 deletion-induced reprogramming of fatty acid metabolism confers chemoresistance in epithelial ovarian cancer.
    Zhu J; Wu G; Song L; Cao L; Tan Z; Tang M; Li Z; Shi D; Zhang S; Li J
    EBioMedicine; 2019 May; 43():238-252. PubMed ID: 31047858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.